---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-000093"
form_type: "8-K"
ticker: "RYTM"
cik: "0001649904"
company_name: "RHYTHM PHARMACEUTICALS, INC."
filed_at: "2025-01-10T23:59:59+00:00"
generated_at: "2026-05-28T05:07:32.158827+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Rhythm Pharma reports preliminary 2024 IMCIVREE sales of $130M, up 68% YoY; Phase 3 HO data on track for H1 2025

## Summary
- Preliminary Q4 2024 IMCIVREE net revenues of ~$42M, up 26% sequentially; full year ~$130M vs $77.4M in 2023.
- U.S. sales contributed ~74% of Q4 and ~73% of full year 2024 revenues.
- Topline data from Phase 3 acquired hypothalamic obesity trial expected in first half of 2025; completed Japanese cohort.
- Phase 3 EMANATE enrollment completed across four substudies; topline data anticipated first half of 2026.
- New Phase 2 trial of setmelanotide in Prader-Willi syndrome to initiate Q1 2025 (up to 20 patients, 26 weeks).

## SEC filing metadata
- accession: 0001558370-25-000093
- form_type: 8-K
- ticker: RYTM
- cik: 0001649904
- company_name: RHYTHM PHARMACEUTICALS, INC.
- filed_at: 2025-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649904/000155837025000093/0001558370-25-000093-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649904/000155837025000093/rytm-20250110x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-000093
- JSON: https://secwatch.observer/filing/0001558370-25-000093.json
- Plain text: https://secwatch.observer/filing/0001558370-25-000093.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.